(RTTNews) - Indian shares were slightly higher in early trade on Thursday as oil prices stabilized and investors pinned hopes on U.S.-China talks yielding positive results on the Iran war.
(RTTNews) - Indian shares were slightly higher in early trade on Thursday as oil prices stabilized and investors pinned hopes on U.S.-China talks yielding positive results on the Iran war.
Earnings Call Insights: Altimmune (ALT) Q1 2026 Management View "In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, resulted in a cash balance of approximately $535 million as of April 30," Jerome Durso said (Chairman, CEO & President). "We now have the financial resources t...
Earnings Call Insights: Altimmune (ALT) Q1 2026 Management View "In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, resulted in a cash balance of approximately $535 million as of April 30," Jerome Durso said (Chairman, CEO & President). "We now have the financial resources to fully fund the company through our Phase III MASH 52-week data readout, which is expected in 2029," Durso said (Chairman, CEO & President), adding, "We expect to initiate our global Phase III study in MASH in the second half of this year" and "the MASH Phase III trial will be called the PERFORMA trial." "We remain on track to report top line data from our Phase II trial next quarter" in alcohol use disorder (AUD), and "in ALD, we now expect to complete enrollment of the RESTORE trial in the third quarter of this year," Durso said (Chairman, CEO & President). "A key strategic focus for the company was securing access to the capital required to successfully drive our clinical programs" and "as of March 31, we reported total cash of $332 million," Gregory Weaver said (Chief Financial Officer), adding, "on a PERFORMA basis, our cash position as of April 30 was $535 million." Outlook "We are well on our way towards initiating the study in the second half of the year," Christophe Arbet-Engels said (Chief Medical Officer), and "this is an important milestone in our global development strategy as the data from the PERFORMA Phase III trial will form the basis for regulatory submissions in multiple regions." "We will introduce the 2.4 milligram pemvidutide dose in Phase III," Arbet-Engels said (Chief Medical Officer), describing PERFORMA as "an event-driven study" with "the interim analysis" at "52 weeks based on biopsy" and stating, "There is no other interim analysis that is planned than these two." "We have another milestone approaching this year with the top line data from the ...
Apple (NasdaqGS:AAPL) CEO Tim Cook is joining President Trump and other top U.S. tech leaders on a business delegation to China. The group is meeting Chinese officials to discuss technology, trade, and regulatory issues that directly affect Apple's position in the country. The summit focuses on market access, product approvals, and longer term cooperation in areas such as hardware and AI. For Appl...
Apple (NasdaqGS:AAPL) CEO Tim Cook is joining President Trump and other top U.S. tech leaders on a business delegation to China. The group is meeting Chinese officials to discuss technology, trade, and regulatory issues that directly affect Apple's position in the country. The summit focuses on market access, product approvals, and longer term cooperation in areas such as hardware and AI. For Apple, China is a key market for iPhone, iPad, Mac, and wearables, as well as a core hub for its...
Honda Motor Co. forecast a rebound in operating profit for the current fiscal year, even after an ill-timed bet on electric vehicles led to a writedown and a record loss. The manufacturer of cars and motorcycles sees profit of ¥500 billion ($3.2 billion) for the period ending March 2027, higher than the consensus estimate of ¥212.4 billion. It posted a ¥414.3 billion shortfall during the previous ...
Honda Motor Co. forecast a rebound in operating profit for the current fiscal year, even after an ill-timed bet on electric vehicles led to a writedown and a record loss. The manufacturer of cars and motorcycles sees profit of ¥500 billion ($3.2 billion) for the period ending March 2027, higher than the consensus estimate of ¥212.4 billion. It posted a ¥414.3 billion shortfall during the previous year, its first annual loss since it was founded in 1948. The Japanese carmaker has struggled to keep up with intense competition as the global automobile industry shifts toward electrification and automation. Honda has insufficient models to tap into renewed demand for gas-electric hybrids in the US, while in China local brands churning out EVs have all but taken over what is now the world’s largest car market. The onus now falls on Chief Executive Officer Toshihiro Mibe to stem further losses and stabilize Honda’s automobile business before it becomes too much of a burden for its more profitable motorcycle unit. “The management group there has been shielded too long by a super profitable motorcycle business that allows them to push problems with the automotive business under the rug,” said Christopher Richter, a senior analyst at CLSA Securities Japan. “The motorcycle business has become a crutch for Honda that prevents them from taking a serious look at their automotive business.” Read More: Honda’s Car Troubles Began Long Before Disastrous Bet on EVs Almost one in three motorcycles sold globally carries the Honda badge. The unit generates a majority of the company’s operating profit despite accounting for less than a fifth of sales. A host of geopolitical challenges — war in the Middle East, US tariffs and a shortage of Chinese semiconductors — have only added to the challenges faced by global carmakers as they navigate the transition toward EVs and software-focused development. Honda first sounded the alarm of a costly slowdown in EV demand in early February. Soon afte...
Mike_Pellinni/iStock via Getty Images Broad U. S. market indices declined during the quarter and dispersion was elevated across sectors. Investors grappled with the conflict in Iran and a related spike in energy prices, in addition to continued AI-related uncertainty. Against this volatile backdrop, energy stocks led the value index higher, while our portfolio declined and underperformed its value...
Mike_Pellinni/iStock via Getty Images Broad U. S. market indices declined during the quarter and dispersion was elevated across sectors. Investors grappled with the conflict in Iran and a related spike in energy prices, in addition to continued AI-related uncertainty. Against this volatile backdrop, energy stocks led the value index higher, while our portfolio declined and underperformed its value benchmark. The financials, technology, and health care sectors were the largest detractors from performance during the quarter. Medicare Advantage (MA) insurer Humana ( HUM ) was the largest individual detractor after CMS (Centers for Medicare and Medicaid Services) proposed a disappointing preliminary MA rate update for 2027. Additionally, management projected rapid growth in its MA membership in 2026, which investors fear may reflect overly rich plan benefit design relative to peers. We view these risks as more timing-related than thesis-changing and added to our position on weakness. Within financials despite reporting results that reflected a stable credit environment, credit card issuer Capital One ( COF ) declined, driven by fear that macroeconomic risk from the Iran conflict, coupled with AI's potential to weigh on employment in the future, could pressure consumer credit quality. Leading IT services provider Cognizant ( CTSH ) was weak, despite reporting robust 4Q earnings with peer-leading organic growth, due to fears around AI disruption to the services industry more broadly. We continue to see these fears as overblown and added to our position on weakness. The energy and industrials sectors contributed positively to performance in the quarter. Commodity chemicals producer Dow ( DOW ) rallied as oil prices spiked, which is expected to tighten global polyethylene markets and benefit Dow due to its cost-advantaged footprint in North America. Integrated oil producer Shell PLC ( SHEL ) also benefited from the rising oil price. Shares of biopharma company Bristol-Myers...